HIP1-ALK Positive Non-Small-Cell Lung Cancer: Clinicopathological Characteristics and Prognosis

被引：0
|
作者：
Wu, F. [1 ]
Zeng, Y. [1 ]
Chen, L. [2 ,3 ,4 ]
Zhou, M. [5 ]
Zhao, X. [6 ]
Luo, Y. [7 ,8 ]
Wu, J. [9 ]
Zhao, L. [1 ]
机构：
[1] Cent South Univ, Xiangya Hosp 2, Dept Oncol, Changsha, Peoples R China
[2] Sun Yat Sen Univ, Dept Med Oncol, Canc Ctr, Guangzhou, Peoples R China
[3] State Key Lab Oncol South China, Guangzhou, Peoples R China
[4] Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China
[5] Guangzhou Med Univ, Affiliated Canc Hosp & Inst, Dept Thorac Surg, Guangzhou, Peoples R China
[6] Fudan Univ, Shanghai Med Coll, Shanghai Canc Ctr, Dept Med Oncol, Shanghai, Peoples R China
[7] Cent South Univ, Hunan Canc Hosp, Dept Radiat Oncol, Changsha, Peoples R China
[8] Cent South Univ, Xiangya Sch Med, Affiliated Canc Hosp, Changsha, Peoples R China
[9] Hunan Canc Hosp, Changsha, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
HIP1-ALK fusion; ALK inhibitor; non-small-cell lung cancer (NSCLC);
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P84.04
引用
收藏
页码：S656 / S657
页数：2
相关论文
共 50 条
  • [21] Clinically Primary and Secondary Resistance to ALK Inhibitors in ALK-Positive Advanced Non-Small-Cell Lung Cancer
    Kang, J.
    Chen, H.
    Zhang, X.
    Zhou, Q.
    Tu, H.
    Yang, J. J.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1895 - S1895
  • [22] ALK-rearrangement in non-small-cell lung cancer (NSCLC)
    Du, Xue
    Shao, Yun
    Qin, Hai-Feng
    Tai, Yan-Hong
    Gao, Hong-Jun
    THORACIC CANCER, 2018, 9 (04) : 423 - 430
  • [23] Brigatinib: Novel ALK Inhibitor for Non-Small-Cell Lung Cancer
    Spencer, Sara A.
    Riley, Angela C.
    Matthew, Adia
    Di Pasqua, Anthony J.
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (06) : 621 - 626
  • [24] Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer
    Shaw, Alice T.
    Kim, Dong-Wan
    Mehra, Ranee
    Tan, Daniel S. W.
    Felip, Enriqueta
    Chow, Laura Q. M.
    Camidge, D. Ross
    Vansteenkiste, Johan
    Sharma, Sunil
    De Pas, Tommaso
    Riely, Gregory J.
    Solomon, Benjamin J.
    Wolf, Juergen
    Thomas, Michael
    Schuler, Martin
    Liu, Geoffrey
    Santoro, Armando
    Lau, Yvonne Y.
    Goldwasser, Meredith
    Boral, Anthony L.
    Engelman, Jeffrey A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (13): : 1189 - 1197
  • [25] Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer
    Shen, Liang
    Ji, Hong-Fang
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (26): : 2537 - 2537
  • [26] First-line lorlatinib for advanced ALK-positive non-small-cell lung cancer
    Lin, Jessica J.
    Gainor, Justin F.
    LANCET RESPIRATORY MEDICINE, 2023, 11 (04): : 302 - 304
  • [27] First-line treatment of advanced ALK-positive non-small-cell lung cancer
    Gandhi, Shipra
    Chen, Hongbin
    Zhao, Yujie
    Dy, Grace K.
    LUNG CANCER-TARGETS AND THERAPY, 2015, 6 : 71 - 82
  • [28] A comparative evaluation of alectinib for ALK-positive non-small-cell lung cancer: A systematic review
    Kharat, Monica
    Nookala, Harshitha
    John, Jabez David
    Patel, Tirath
    Kalyandrug, Pragnesh
    Emmanuel, Sonya
    Noor, Anaya
    Halani, Dhruv Jignesh Kumar
    Goyal, Abhishek
    Anand, Nikhilesh
    Gadad, Bharathi
    Millis, Richard M.
    MEDICINE, 2025, 104 (07)
  • [29] The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer
    Amanam, Idoroenyi
    Gupta, Rohan
    Mambetsariev, Isa
    Salgia, Ravi
    FUTURE ONCOLOGY, 2018, 14 (19) : 1897 - 1908
  • [30] Canadian consensus: inhibition of ALK-positive tumours in advanced non-small-cell lung cancer
    Melosky, B.
    Agulnik, J.
    Albadine, R.
    Banerji, S.
    Bebb, D. G.
    Bethune, D.
    Blais, N.
    Butts, C.
    Cheema, P.
    Cheung, P.
    Cohen, V.
    Deschenes, J.
    Ionescu, D. N.
    Juergens, R.
    Kamel-Reid, S.
    Laurie, S. A.
    Liu, G.
    Morzycki, W.
    Tsao, M. S.
    Xu, Z.
    Hirsh, V.
    CURRENT ONCOLOGY, 2016, 23 (03) : 196 - 200
12345